Open AccessPreclinical evaluation of [111In]-DOTA-trastuzumab for clinical trials
Author(s) -
Behrouz Alirezapour,
Amir Reza Jalilian,
S. Rajabifar,
M. Mirzaii,
Shirin Moradkhani,
Mehraban Pouladi,
Gholamreza Aslani
Publication year - 2014
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.131434
Subject(s) - dota , skbr3 , trastuzumab , internalization , radioimmunoassay , chemistry , context (archaeology) , in vivo , in vitro , conjugate , antibody , nuclear medicine , microbiology and biotechnology , medicine , chelation , cell , cancer , immunology , cancer cell , biochemistry , breast cancer , biology , mathematical analysis , human breast , mathematics , organic chemistry , paleontology
Herceptin and its fragments have been radiolabeled and used in the imaging of human epidermal growth factor receptor 2 (HER2)/neu-positive tumors and development of diagnostic kits is of great importance in radiopharmacy.